<?xml version="1.0" encoding="UTF-8"?>
<ref id="B45">
 <label>45</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>You</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Jiang</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Lu</surname>
    <given-names>Q</given-names>
   </name>
   <name>
    <surname>Zhou</surname>
    <given-names>Q</given-names>
   </name>
   <name>
    <surname>Liao</surname>
    <given-names>X</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells</article-title>. 
  <source>Sci China Life Sci</source> (
  <year>2016</year>) 
  <volume>59</volume>(
  <issue>4</issue>):
  <page-range>386–97</page-range>.  
  <pub-id pub-id-type="doi">10.1007/s11427-016-5024-7</pub-id>
 </mixed-citation>
</ref>
